4-氯-1,3-二甲基-1H-吡唑[3,4-b]吡啶-5-羧胺 | 175201-98-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 中文名称: 4-氯-1,3-二甲基-1H-吡唑[3,4-b]吡啶-5-羧胺
• 中文别名: 4-氯-1,3-二甲基-1H-吡唑[3,4-B]吡啶-5-羧胺
• 英文名称: 4-chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
• 英文别名: 4-chloro-1,3-dimethylpyrazolo[5,4-b]pyridine-5-carboxamide；4-chloro-1,3-dimethylpyrazolo[5,4-b] pyridine-5-carboxamide；4-chloro-1,3-dimethylpyrazolo[3,4-b]pyridine-5-carboxamide
• CAS: 175201-98-6
• 化学式: C₉H₉ClN₄O
• mdl: MFCD00067963
• 分子量: 224.65
• InChiKey: PBNJVZMMMDZVIA-UHFFFAOYSA-N

物化性质

• 熔点：
  275 °C
• 沸点：
  412.4±45.0 °C(Predicted)
• 密度：
  1.57±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  73.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090

SDS

Name:	4-Chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide, 97% Material Safety Data Sheet
Synonym:
CAS:	175201-98-6

Section 1 - Chemical Product MSDS Name: 4-Chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide, 97% Material Safety Data Sheet
Synonym:

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175201-98-6	4-Chloro-1,3-dimethyl-1H-pyrazolo[3,4-	97%	unlisted

+++++
Hazard Symbols: XI

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Irritating to eyes, respiratory system and skin. Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 175201-98-6: Personal Protective Equipment
Eyes:
Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Solid
Color: light beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 255 - 257 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H9ClN4O
Molecular Weight: 225

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide, ammonia.
Hazardous Polymerization: Has not been reported

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 175201-98-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA No information available. IMO No information available. RID/ADR No information available.

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S 37/39 Wear suitable gloves and eye/face protection. WGK (Water Danger/Protection) CAS# 175201-98-6: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 175201-98-6 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 175201-98-6 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 4/04/2003 Revision #0 Date: Original. The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氯-1,3-二甲基-1H-吡唑[3,4-b]吡啶-5-羧胺 在 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 8.0h， 生成 3-{[5-(aminocarbonyl)-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}benzoic acid
  参考文献：
  名称：

  New orally active PDE4 inhibitors with therapeutic potential

  摘要：

  The design synthesis, and biological evaluation of a series of pyrazolopyridines was carried out. Structural optimization of the aniline moiety of 4-anilinopyrazolopyridinc derivative 3a, which is one of the newly discovered chemical leads for PDE4 inhibitors from our in-house library, was performed successfully. The details of the discovery of new orally active PDE4 inhibitors, which are expected to show therapeutic potential, are presented and their structure-activity relationships are discussed. Pharmacological evaluation and pharmacokinetic data for representative compounds are also presented. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.05.032
• 作为产物：
  描述：

  5-氨基-1,3-二甲基吡唑 在 氢氧化钾 、 ammonium hydroxide 、 氯化亚砜 、 三氯氧磷 作用下， 以 1,4-二氧六环 为溶剂， 生成 4-氯-1,3-二甲基-1H-吡唑[3,4-b]吡啶-5-羧胺
  参考文献：
  名称：

  具有治疗潜力的新型口服活性PDE4抑制剂。

  摘要：

  已成功进行了吡唑并吡啶衍生物2的结构优化，吡唑并吡啶衍生物2是我们内部库中新发现的PDE4抑制剂的化学前导之一。介绍了有望具有治疗潜力的新型口服活性PDE4抑制剂的发现过程，并讨论了它们的构效关系。

  DOI：

  10.1016/j.bmcl.2003.10.025

文献信息

• Discovery of New Orally Active Phosphodiesterase (PDE4) Inhibitors
  作者：Hiroshi Ochiai、Akiharu Ishida、Tazumi Ohtani、Kensuke Kusumi、Katuya Kishikawa、Susumu Yamamoto、Hiroshi Takeda、Takaaki Obata、Hisao Nakai、Masaaki Toda

  DOI：10.1248/cpb.52.1098

  日期：——

  A series of 4-anilinopyrazolopyridine derivatives were synthesized and biologically evaluated as inhibitors of phosphodiesterase (PDE4). Chemical modification of 3, a structurally new chemical lead that was found in our in-house library, was focused on 1- and 3-substituents. Full details of the discovery of a new orally active chemical lead 5 are presented. Structure–activity relationship data, pharmacological evaluation, and the subtype selectivity study are also presented.

  合成了一系列4-氨基吡唑并吡啶衍生物，并对其作为磷酸二酯酶（PDE4）抑制剂进行生物评估。对3这一我们内部库中发现的结构新颖的化学先导物的化学改造主要集中在1-和3-取代基上。本文详细介绍了新型口服活性化学先导物5的发现，以及结构-活性关系数据、药理评估和亚型选择性研究的结果。
• Antagonists of MCP-1 function and methods of use thereof
  申请人：——

  公开号：US20030096705A1

  公开（公告）日：2003-05-22

  The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.

  本发明涉及化合物、包含该化合物的药物组合物、使用该化合物和组合物的用途、使用该化合物和组合物的治疗方法，以及制备该化合物的过程。具体而言，本发明涉及新型化合物，这些化合物是 MCP-1 功能拮抗剂，可用于预防或治疗慢性或急性炎症性或自身免疫性疾病，特别是那些与淋巴细胞或单核细胞异常积聚有关的疾病，如关节炎、哮喘、动脉粥样硬化、糖尿病肾病、炎性肠病、克罗恩病、多发性硬化、肾炎、胰腺炎、肺纤维化、银屑病、再狭窄和移植排斥反应。更具体地，本发明涉及包含这些化合物的药物组合物以及使用这些化合物和组合物预防或治疗这些疾病。
• Macrolide antibiotics
  申请人：——

  公开号：US20040077557A1

  公开（公告）日：2004-04-22

  The present invention relates to 11,12 &ggr; lactone ketolides of formula (I) wherein R, R 1 , R 2 , R 3 are as defined herein and pharmaceutically acceptable salts and solvates thereof, to process for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body.

  本发明涉及公式（I）中的11,12 &ggr;内酯酮类化合物，其中R、R1、R2、R3如本文所定义的，以及其药学上可接受的盐和溶剂化物，以及它们的制备方法及在人或动物体内治疗或预防全身或局部细菌感染中的应用。
• Macrolide Antibiotics
  申请人：ALIHODZIC Sulejman

  公开号：US20060211636A1

  公开（公告）日：2006-09-21

  The present invention relates to 11,12 γ lactone ketolides of formula (I) wherein R, R 1 , R 2 , R 3 are as defined herein and pharmaceutically acceptable salts and solvates thereof, to process for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body.

  本发明涉及式(I)的11,12-γ内酯酮类化合物，其中R、R1、R2、R3如定义所述，以及其药学上可接受的盐和溶剂化物，以及其制备方法和在人或动物体内治疗或预防系统性或局部细菌感染的用途。
• NITROGENOUS HETEROCYCLIC COMPOUNDS
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1067123A1

  公开（公告）日：2001-01-10

  The present invention relates to nitrogen-containing heterocyclic compounds represented by formula (I): wherein W represents 1,4-piperazinediyl, etc.; U represents NR1R2 (wherein R1 represents a hydrogen atom, a substituted or unsubstituted alkyl group, etc.; and R2 represents a hydrogen atom, etc.), OR4, or SR5; V represents an oxygen atom, a sulfur atom, N-R6, or CR7R8, at least one of X, Y and Z represents a nitrogen atom, and the others are the same or different, and each represents a nitrogen atom or C-RA; and D1, D2, D3 and D4 each independently represent C-RB, a nitrogen atom, an oxygen atom, a sulfur atom, etc., optional adjoining two among D1 to D4 are combined to represent a nitrogen atom, N-R2A, an oxygen atom, a sulfur atom, etc., or optional adjoining two selected from D1 to D4 represent C-RB'' (wherein two RB''s are combined to represent substituted or unsubstituted alicyclic alkene, substituted or unsubstituted pyrrole, substituted or unsubstituted pyrazole, etc.; or pharmaceutically acceptable salts thereof.

  本发明涉及式（I）所代表的含氮杂环化合物： 其中 W 代表 1，4-哌嗪二基等；U 代表 NR1R2（其中 R1 代表氢原子、取代或未取代的烷基等；R2 代表氢原子等。)、OR4 或 SR5；V 代表氧原子、硫原子、N-R6 或 CR7R8，X、Y 和 Z 中至少有一个代表氮原子，其他的相同或不同，各自代表氮原子或 C-RA；D1、D2、D3 和 D4 各自独立地代表 C-RB、氮原子、氧原子、硫原子等、D1至D4中任选相邻的两个结合代表氮原子、N-R2A、氧原子、硫原子等，或任选相邻的选自D1至D4的两个代表C-RB''（其中两个RB''结合代表取代或未取代的脂环烯、取代或未取代的吡咯、取代或未取代的吡唑等）；或其药学上可接受的盐。